Regulus Therapeutics

+$0.025 (+3.47%) As of 1:01 PM UTC pre-market

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RGLS and other ETFs, options, and stocks.

About RGLS

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development.

CEO
Joseph P. Hagan
Employees
24
Headquarters
San Diego, California
Founded
2007

RGLS Key Statistics

Market Cap
62.67M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.01M
High Today
$0.745
Low Today
$0.70
Open Price
$0.70
Volume
695.22K
52 Week High
$2.32
52 Week Low
$0.45

RGLS Earnings

-$0.25
-$0.17
-$0.08
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected Nov 4, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure